{"entity":{"id":"hck","kind":"target","name":"HCK kinase","aka":[],"tldr":"HCK is a SRC-family kinase of white blood cells that dasatinib and bosutinib inhibit; it drives growth in some leukaemias and in Waldenstrom macroglobulinaemia, where ibrutinib also hits it.","summary":"Haematopoietic cell kinase (HCK) is a SRC-family tyrosine kinase restricted to myeloid cells and B lymphocytes. It is one of the SRC kinases blocked by dasatinib and bosutinib, and in chronic myeloid leukaemia it associates with BCR-ABL and helps drive STAT5 signalling. In Waldenstrom macroglobulinaemia the MYD88 L265P mutation switches HCK on, and part of the activity of ibrutinib in that disease comes from inhibiting HCK as well as BTK. HCK is also being studied as a target in colorectal cancer, where it is active in tumour-associated macrophages.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/HCK","links":[{"label":"UniProt P08631: HCK","url":"https://www.uniprot.org/uniprotkb/P08631/entry"},{"label":"HGNC:4840 HCK","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4840"},{"label":"ChEMBL target CHEMBL3234","url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3234"}],"tags":["chembl-gap"],"related":["lyn","btk","src"],"cancers":["cml","waldenstrom","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["dasatinib","bosutinib","ibrutinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"HCK","role":[],"sources":[],"specificity":"lineage-antigen","distribution":"few-types","specificityNote":"Lineage antigen shared with normal dendritic cells and granulocytes and monocytes and lymphoid tissue cells: HPA finds the gene tissue enhanced in lymphoid tissue, and the 3 medicines aimed at it (Dasatinib, Bosutinib, Ibrutinib) act on the wild-type protein, so the normal lineage is hit too. HPA HCK: RNA tissue enhanced (lymphoid tissue 107 nTPM); blood lineage group enriched (dendritic cells 336 nTPM, granulocytes 803 nTPM, monocytes 1,255 nTPM); no normal tissue stained high; highest cancer staining endometrial cancer (2 of 11 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Lymphoma, Colorectal cancer); Open Targets associates it with 2 specific cancer types at or above 0.5 (chronic myeloid leukemia, acute lymphoblastic leukemia). (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas HCK tissue","url":"https://www.proteinatlas.org/ENSG00000101336-HCK/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas HCK pathology","url":"https://www.proteinatlas.org/ENSG00000101336-HCK/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000101336 associations","url":"https://platform.opentargets.org/target/ENSG00000101336/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:4840","ensembl":"ENSG00000101336","uniprot":"P08631","entrez":"3055","firstDescribed":1987,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Quintrell et al, Mol. Cell. Biol, 1987, \"Identification of a human gene (HCK) that encodes a protein-tyrosine kinase and is expressed in hemopoietic cells\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/3496523/","biology":"A non-receptor tyrosine kinase downstream of Fc, integrin and Toll-like receptors in myeloid cells; it activates STAT5, PI3K and MAPK pathways.","whereFound":["Monocytes, macrophages, neutrophils and B cells","CML and Waldenstrom macroglobulinaemia cells"],"targetClass":"kinase","prevalence":[{"cancerId":"metastatic-cancer","pct":"all","measure":"Signalling protein present in most cells (HCK kinase, mainly in white blood cells); drugs act on the pathway rather than on a mutation that selects patients, so no prevalence applies."}]},"route":"/targets/hck/","neighbours":{"target":[{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"},{"id":"lyn","kind":"target","name":"LYN kinase","route":"/targets/lyn/"},{"id":"src","kind":"target","name":"SRC family kinases","route":"/targets/src/"}],"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"drug":[{"id":"bosutinib","kind":"drug","name":"Bosutinib","route":"/drugs/bosutinib/"},{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/"},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"}]}}